Outcome of Board Meeting held today i.e. 29th May, 2026
3BBLACKBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
3B BlackBio Dx Ltd (formerly Kilpest India Ltd) held its Board Meeting on May 29, 2026, approving audited standalone and consolidated financial results for Q4 and FY ended March 31, 2026. Standalone revenue grew 7.5% to Rs 9,727.50 lakhs, while consolidated revenue surged 47% to Rs 14,191.81 lakhs, driven by the acquisition of Coris Bioconcept SRL, Belgium. Standalone PAT increased 3.7% to Rs 4,931.69 lakhs, while consolidated PAT rose 25.7% to Rs 5,992.98 lakhs. The Board recommended a final dividend of Rs 5 per share (50% on face value of Rs 10). Auditors Baheti & Company issued unmodified (clean) opinions on both standalone and consolidated results. The company also appointed M/s Ali Jain & Sharma as Internal Auditor for FY 2026-27.
Strong consolidated performance with 47% revenue growth and 25.7% PAT growth signals robust expansion from the Belgian acquisition. The clean audit opinion and dividend recommendation are positive for shareholders. The stock could see upward movement given the solid earnings growth.